Related references
Note: Only part of the references are listed.Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Jeffrey L. Lennox et al.
ANNALS OF INTERNAL MEDICINE (2014)
Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients
S. Bonora et al.
CURRENT HIV RESEARCH (2014)
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
Antonio D'Avolio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
Dinko Rekic et al.
AAPS JOURNAL (2013)
Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients
Sylvain Goutelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Negligible Effect of Tenofovir on Atazanavir Trough Concentrations and Genotypic Inhibitory Quotients in the Presence and Absence of Ritonavir
Cassandra Fournier et al.
THERAPEUTIC DRUG MONITORING (2013)
Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine
Kathleen E. Squires et al.
HIV CLINICAL TRIALS (2012)
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
Li Zhu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients
Stefano Bonora et al.
ANTIVIRAL THERAPY (2011)
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy
Juliette Pavie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Factors predictive of virological failure on atazanavir in 310 HIV-infected patients
Francois-Xavier Lescure et al.
AIDS (2010)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Alessandro Schipani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn et al.
ANTIVIRAL THERAPY (2010)
Tenofovir Coadministration Is Not Associated With Lower Unboosted Atazanavir Plasma Exposure in the Clinical Setting
Andrea Caleagno et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients
Antonio D'Avolio et al.
THERAPEUTIC DRUG MONITORING (2008)
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia: Genetic screening is unnecessary
RE Nettles et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
AM Taburet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Share Paper
